联系方式：400-650-8506
CNEN
产品名称 BMS 303141
产品货号 Axon 2506 CAS [943962-47-8] MF C19H15Cl2NO4SMW 424.30 Purity: 100% Soluble in DMSO and Ethanol Description Cell-permeable ATP-citrate lyase (ACL) inhibitor (IC50 value 0.13 µM in vitro, and 8 µM for inhibition of total lipid syntheses in HepG2 cells). When administered to mice fed on a high-fat diet, it produced an approximate 20–30% lowering in plasma cholesterol and triglycerides, as well as a 30–50% decrease in fasting plasma glucose, as well as an inhibition of weight gain. BMS 303141 also showed inhibitory effects for other metabolic disease related targets such as ACC1 and ACC2 (IC50 values 6 µM and 12 µM, respectively). KEYWORDS: BMS 303141 | supplier | ACL inhibitor | BMS303141 | CAS [943962-47-8] | ADP | ACL | ATP-citrate lyase | Inhibitor | metabolic disorders | diabetes | obesity | dyslipidemia | acetyl-CoA | fatty acid | cholesterol | cardiovascular | LDL | HDL | weight gain | triglycerides
产品价格 现货询价，电话：010-67529703
产品规格
产品品牌 axonmedchem
产品概述
产品详情

BMS 303141

Based on 16 reference(s) in Google Scholar 9 10 16

Axon 2506

CAS [943962-47-8]

MF C19H15Cl2NO4S
MW 424.30

  • Purity: 100%
  • Soluble in DMSO and Ethanol

BMS 303141

Description

Cell-permeable ATP-citrate lyase (ACL) inhibitor (IC50 value 0.13 µM in vitro, and 8 µM for inhibition of total lipid syntheses in HepG2 cells). When administered to mice fed on a high-fat diet, it produced an approximate 20–30% lowering in plasma cholesterol and triglycerides, as well as a 30–50% decrease in fasting plasma glucose, as well as an inhibition of weight gain. BMS 303141 also showed inhibitory effects for other metabolic disease related targets such as ACC1 and ACC2 (IC50 values 6 µM and 12 µM, respectively).

KEYWORDS: BMS 303141 | supplier | ACL inhibitor | BMS303141 | CAS [943962-47-8] | ADP | ACL | ATP-citrate lyase | Inhibitor | metabolic disorders | diabetes | obesity | dyslipidemia | acetyl-CoA | fatty acid | cholesterol | cardiovascular | LDL | HDL | weight gain | triglycerides
产品资料